TrialClinical cancer research : an official journal of the American Association for Cancer Research2026
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Danny Rischin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.